Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Registration Number
- NCT04324151
- Lead Sponsor
- Hunan Province Tumor Hospital
- Brief Summary
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
- Detailed Description
Inclusion criteria:
diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- Potentially Resectable NSCLC
- Treatment Plan is Crizotinb or Standard Chemotherapy
Exclusion Criteria
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS may 2020- may 2021 (1 year) Progression free survival
- Secondary Outcome Measures
Name Time Method OS may 2020- may 2021 (1 year) Overall survival
ORR may 2020- may 2021 (1 year) To measure the patients's overall response rate
Trial Locations
- Locations (1)
Yongchang Zhang
🇨🇳Changsha, Hunan, China